Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: A meta-analysis of observational studies

Journal of Interventional Cardiac Electrophysiology

Volumn 37, Issue 3, 2013, Pages 213-221

  Steinberg, Benjamin A ^a,b   Hasselblad, Vic ^b   Atwater, Brett D ^a   Bahnson, Tristram D ^a,b   Washam, Jeffrey B ^c   Alexander, John H ^b   Daubert, James P ^a,b   Piccini, Jonathan P ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c DUKE UNIVERSITY   (United States)

Author keywords

Ablation; Atrial fibrillation; Dabigatran; Meta analysis; Warfarin

Indexed keywords

CERTOPARIN; DABIGATRAN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADVERSE OUTCOME; ANTICOAGULATION; ARTICLE; ATTRIBUTABLE RISK; BLEEDING; CATHETER ABLATION; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART TAMPONADE; HUMAN; MAXIMUM LIKELIHOOD METHOD; META ANALYSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PEER REVIEW; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION;

ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; CATHETER ABLATION; COMORBIDITY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSERVATIONAL STUDY AS TOPIC; POSTOPERATIVE COMPLICATIONS; PREMEDICATION; RISK FACTORS; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 84882265578     PISSN: 1383875X     EISSN: 15728595     Source Type: Journal    
DOI: 10.1007/s10840-013-9813-7     Document Type: Article

References (32)

1. Fuster, V.; Ryden, L. E.; Cannom, D. S.; Crijns, H. J.; Curtis, A. B.; Ellenbogen, K. A.; et al. (2011). 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation, 123(10), e269-367, doi: 10.1161/CIR.0b013e318214876d
2. Calkins, H.; Kuck, K. H.; Cappato, R.; Brugada, J.; Camm, A. J.; Chen, S. A.; et al. (2012). 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design: a report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society. Journal of Interventional Cardiac Electrophysiology.
3. Cappato, R.; Calkins, H.; Chen, S. A.; Davies, W.; Iesaka, Y.; Kalman, J.; et al. (2010). Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol, 3(1), 32-38, doi: 10.1161/CIRCEP.109.859116
4. Natale, A.; Raviele, A.; Arentz, T.; Calkins, H.; Chen, S. A.; Haissaguerre, M.; et al. (2007). Venice Chart international consensus document on atrial fibrillation ablation. Journal of Cardiovascular Electrophysiology, 18(5), 560-580.
5. Connolly, S. J.; Ezekowitz, M. D.; Yusuf, S.; Eikelboom, J.; Oldgren, J.; Parekh, A.; et al. (2009). Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 361(12), 1139-1151, doi: 10.1056/NEJMoa0905561
6. Beasley, B. N.; Unger, E. F.; & Temple, R. (2011). Anticoagulant options - why the FDA approved a higher but not a lower dose of dabigatran. The New England Journal of Medicine, 364(19), 1788-1790. doi: 10.1056/NEJMp1103050.
7. Liberati, A.; Altman, D. G.; Tetzlaff, J.; Mulrow, C.; Gotzsche, P. C.; Ioannidis, J. P.; et al. (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Annals of Internal Medicine, 151(4), W65-W94.
8. Moher, D.; Liberati, A.; Tetzlaff, J.; & Altman, D. G. (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine, 6(7), e1000097. doi: 10.1371/journal.pmed.1000097.
9. Hasselblad, V.; Mosteller, F.; Littenberg, B.; Chalmers, T. C.; Hunink, M. G.; Turner, J. A.; et al. (1995). A survey of current problems in meta-analysis. Discussion from the Agency for Health Care Policy and Research inter-PORT Work Group on Literature Review/Meta-Analysis. Medical Care, 33(2), 202-220.
10. Bunch, T. J.; Crandall, B. G.; Weiss, J. P.; Osborn, J. S.; May, H. T.; & Day, J. D. (2011). Pradaxa can be safely used as monotherapy or as a bridge to therapeutic warfarin after atrial fibrillation ablation. Circulation, 124(21).
11. Eitel, C.; Hindricks, G.; & Piorkowski, C. (2012). Dabigatran in patients post atrial fibrillation ablation. Journal of the American College of Cardiology, 59(13), E603.
12. Winkle, R. A.; Mead, R. H.; Engel, G.; Kong, M. H.; & Patrawala, R. A. (2012). The use of dabigatran immediately after atrial fibrillation ablation. Journal of Cardiovascular Electrophysiology, 23(3), 264-268. doi: 10.1111/j.1540-8167.2011.02175.x.
13. Yamaji, H.; Murakami, T.; Kawamura, H.; Murakami, M.; & Hina, K. (2012). Safety of dabigatran for atrial fibrillation ablation as a periprocedural anticoagulation strategy. Heart Rhythm, 9(5), S170.
14. Nin, T.; Sairaku, A.; Yoshida, Y.; Kamiya, H.; Tatematsu, Y.; Nanasato, M.; et al. (2012). A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation. Pacing and Clinical Electrophysiology, 36(2), 172-179. doi: 10.1111/pace.12036.
15. Gangireddy, S.; Coffey, J. O.; Calenda, B. W.; Teh, A.; Miller, M.; Skipitaris, N. T.; et al. (2012). The incidence of stroke after atrial fibrillation ablation in patients on dabigatran. Heart Rhythm, 9(5), S472.
16. Mendoza, I.; Helguera, M.; Baez-Escudero, J.; Reina, J.; & Pinski, S. L. (2012). Atrial fibrillation ablation on uninterrupted anticoagulation with dabigatran versus warfarin. Heart Rhythm, 9(5), S270-S271. Abstract.
17. Rowley, C. P.; Bradford, N. S.; Bernard, M. L.; Sidney, D. S.; Brabham, W. W.; Netzler, P. C.; et al. (2012). Complications of atrial fibrillation ablation in patients anticoagulated with dabigatran compared to warfarin. Heart Rhythm, 9(5), S201.
18. Ellis, C. R.; Streur, M. M.; & Nagarakanti, R. (2012). Safety and efficacy of dabigatran versus warfarin in patients undergoing left atrial catheter ablation. Heart Rhythm, 9(5), S421.
19. Lakkireddy, D.; Reddy, Y. M.; Di Biase, L.; Vanga, S. R.; Santangeli, P.; Swarup, V.; et al. (2012). Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation results from a multicenter prospective registry. Journal of the American College of Cardiology, 59(13), 1168-1174. doi: 10.1016/j.jacc.2011.12.014.
20. Kaseno, K.; Naito, S.; Nakamura, K.; Sakamoto, T.; Sasaki, T.; Tsukada, N.; et al. (2012). Efficacy and safety of periprocedural dabigatran in patients undergoing catheter ablation of atrial fibrillation. Circulation journal, 76(10), 2337-42.
21. Snipelisky, D.; Kauffman, C.; Prussak, K.; Johns, G.; Venkatachalam, K.; & Kusumoto, F. (2012). A comparison of bleeding complications post-ablation between warfarin and dabigatran. Journal of Interventional Cardiac Electrophysiology, 35(1), 29-33. doi: 10.1007/s10840-012-9708-z.
22. Kim, J. S.; She, F.; Jongnarangsin, K.; Chugh, A.; Latchamsetty, R.; Ghanbari, H.; et al. (2012). Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm. doi: 10.1016/j.hrthm.2012.12.011.
23. Maddox, W.; Kay, G. N.; Yamada, T.; Osorio, J.; Doppalapudi, H.; Plumb, V. J.; et al. (2013). Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation. Journal of Cardiovascular Electrophysiology, n/a-n/a. doi: 10.1111/jce.12143.
24. Haines, D. E.; Mead-Salley, M.; Salazar, M.; Marchlinski, F. E.; Zado, E.; Calkins, H.; et al. (2013). Dabigatran versus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation. Journal of Interventional Cardiac Electrophysiology. doi: 10.1007/s10840-013- 9800-z.
25. Bassiouny, M.; Saliba, W.; Rickard, J.; Shao, M.; Sey, A.; Diab, M.; et al. (2013). Use of dabigatran for peri-procedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. Circulation Arrhythm Electrophysiology, Epub. doi: 10.1161/circep.113.000320.
26. Boehringer-Ingelheim. (2010). Dabigatran prescribing information. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase= renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf. Accessed 14 May 2011.
27. Cohen, M.; Mahaffey, K. W.; Pieper, K.; Pollack, C. V.; Jr.; Antman, E. M.; Hoekstra, J.; et al. (2006). A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes. Journal of the American College of Cardiology, 48(7), 1346-1354. doi: 10.1016/j.jacc.2006.05.058.
28. White, H. D.; Chew, D. P.; Hoekstra, J. W.; Miller, C. D.; Pollack, C. V.; Jr.; Feit, F.; et al. (2008). Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. Journal of the American College of Cardiology, 51(18), 1734-1741. doi: 10.1016/j.jacc.2007.12.052.
29. Huang, C.; Siu, M.; Vu, L.; Wong, S.; & Shin, J. (2012). Factors influencing doctors' selection of dabigatran in non-valvular atrial fibrillation. Journal of Evaluation in Clinical Practice, Epub. doi: 10.1111/j.1365-2753.2012.01886.x.
30. Eikelboom, J. W.; Wallentin, L.; Connolly, S. J.; Ezekowitz, M.; Healey, J. S.; Oldgren, J.; et al. (2011). Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation, 123(21), 2363-2372. doi: 10.1161/circulationaha.110. 004747.
31. Healey, J. S.; Eikelboom, J.; Douketis, J.; Wallentin, L.; Oldgren, J.; Yang, S.; et al. (2012). Peri-procedural bleeding and thromboembolic events with dabigatran compared to warfarin: results from the RE-LY Randomized Trial. Circulation, 126(3), 343-348. doi: 10.1161/circulationaha.111.090464.
32. Schirmer, S. H.; Baumhakel, M.; Neuberger, H. R.; Hohnloser, S. H.; van Gelder, I. C.; Lip, G. Y.; et al. (2010). Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments. Journal of the American College of Cardiology, 56(25), 2067-2076. doi: 10.1016/j.jacc.2010.09.017.